ClinicalTrials.gg
Active, not recruitingNCT06921928Updated Jul 31, 2026

Study for AZD4360 in Participants With Advanced Solid Tumours

A Phase 1/2 interventional study of AZD4360 in Gastric Cancer, Gastroesophageal Junction Cancer and Biliary Tract Cancer, sponsored by AstraZeneca. Active, not recruiting at 14 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.

Enrollment
24th of 27
31 · median 124
Started
2025
with 4 others
Phase 1/2
7 of 30
2 open now
Primary completion
2027-03
later than 6 of 17 live
Registered
24th of 30
by date

Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 6 of the 17 other live ones, and was the 24th registered.

Stomach Neoplasms

3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stomach Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Biliary Tract Cancer
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Biliary Tract Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Advanced Solid Tumours
  • AZD4360
  • Claudin 18.2
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 at the time of signing the ICF.
  2. performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
  3. Minimum of 12 weeks in the opinion of the Investigator.

4 Adequate organ and marrow function, as defined by protocol.

5. use by men or women should be consistent with local regulations, as defined by protocol.

6. confirmed advanced or Pancreatic ductal adenocarcinoma (PDAC), Gastric or Gastroesophageal junction cancer (G/GEJC), and Biliary tract cancer (BTC) with documented positive CLDN18.2 expression.

7. Participants must have received at least one in the advanced/metastatic disease.

8. At least one according to v1.1.

Exclusion criteria

Exclusion Criteria:

  1. Human Epidermal Growth Factor Receptor 2 () positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate G/GEJC participants.
  2. Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to bleeding in the setting of prior CLDN18.2 directed therapy.
  3. Participants with clinically significant ascites that require drainage.
  4. Central nervous system (CNS) or CNS pathology, as defined by protocol.
  5. With spinal cord compression or with high risk of paralysis.
  6. History of non-infectious interstitial lung disease/pneumonitis.
  7. Participant has cardiac abnormalities, as defined by protocol.
  8. History of another primary within 2 years prior to screening.
  9. Known serologic status reflecting active or .
  10. Known infection that is not well controlled.
  11. Active tuberculosis infection.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    AZD4360 Monotherapy

    AZD4360 Monotherapy

    Drug: AZD4360

Interventions

  • DrugAZD4360

    Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)

06

What researchers measure

Primary outcomes

  1. Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360

    To investigate the safety and tolerability, and to determine the Maximum Tolerated Dose (MTD) and/or a Recommended Phase II Dose (R2PD) of AZD4360 in previously treated participants with advanced solid tumours, through the assessment of Dose Limiting Toxicities, Adverse Events and Severe Adverse Events.

    Time frame: Through study completion, up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR). Radiological response evaluated according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.

    Time frame: Through study completion, up to approximately 2 years

  2. Duration of Response (DoR)

    The time from the date of first documented ORR until date of first documented Progression of Disease (PD) or death. Radiological response evaluated according to RECIST v1.1.

    Time frame: Through study completion, up to approximately 2 years

  3. Disease Control Rate (DCR)

    The percentage of participants who have a best objective response of confirmed CR or PR or who have Stable Disease for at least 11 weeks after start of treatment to allow for an early assessment within the assessment window. Radiological response evaluated according to RECIST v1.1.

    Time frame: Through study completion, up to approximately 2 years

  4. Progression Free Survival (PFS)

    The time from the start of treatment until the date of objective PD or death. Radiological response evaluated according to RECIST v1.1.

    Time frame: Through study completion, up to approximately 2 years

  5. Overall Survival (OS)

    The time from the start of treatment until death due to any cause.

    Time frame: Through study completion, up to approximately 2 years

  6. Plasma pharmacokinetics (PK) parameters of AZD4360: Plasma concentration

    Plasma concentration of AZD4360, total antibody and other analytes.

    Time frame: Through study completion, up to approximately 2 years

  7. Plamsa PK parameters of AZD4360, total antibody and other analytes: Area Under Curve (AUC)

    Area under the plasma concentration versus time curve for AZD4360, total antibody and other analytes.

    Time frame: Through study completion, up to approximately 2 years

  8. Plasma PK parameters of AZD4360, total antibody and other analytes: Maximum plasma concentration (Cmax)

    Maximum observed plasma concentration of AZD4360, total antibody and other analytes.

    Time frame: Through study completion, up to approximately 2 years

  9. Plasma PK parameters of AZD4360, total antibody and other analytes: Time to maximum plasma concentration (tmax)

    The time it takes for AZD4360, total antibody and other analytes to reach the maximum plasma concentration after administration of the study drug.

    Time frame: Through study completion, up to approximately 2 years

  10. Plasma PK parameters of AZD4360, total antibody and other analytes: Clearance

    A pharmacokinetic measurement of the volume of plasma from which AZD4360, total antibody and other analytes are completely removed per unit time.

    Time frame: Through study completion, up to approximately 2 years

  11. Plasma PK parameters of AZD4360, total antibody and other analytes: Half-life

    The time required for the quantity of AZD4360, total antibody and other analytes to reduce to half of their initial values.

    Time frame: Through study completion, up to approximately 2 years

07

Study locations

14 sites
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Beijing, 100730, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Shanghai, 201318, China
  • Research Site
    Wuhan, 430040, China
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Glasgow, G12 0YN, United Kingdom
  • Research Site
    London, EC1A 7BE, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 90 industry-sponsored phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 109. This study's planned 23 months is below that.

Counting every sponsor, half of 157 studies reached it within 60 months; a quarter within 40 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 10, 2025
StartActual
Apr 29, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Dec 16, 2027
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06921928
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Apr 29, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 16, 2027 (estimated)
Last update
Jul 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion